Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Beta 2 Glycoprotein I antibody, each

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86146 refers to the laboratory test for the detection of beta 2 glycoprotein I antibodies in a blood sample. These antibodies are part of a diverse group of autoantibodies that are primarily associated with antiphospholipid syndrome (APS), a condition that can lead to serious complications such as recurrent venous or arterial thrombosis and fetal losses. The presence of these antibodies is significant in the diagnosis of APS, as they indicate an autoimmune response that may contribute to the formation of blood clots. In clinical practice, when a patient is suspected of having APS, healthcare providers will typically order this test to measure the levels of anti-beta-2 glycoprotein I antibodies, specifically looking for the immunoglobulin G (IgG) and immunoglobulin M (IgM) types. It is important to note that testing for these antibodies is generally conducted on two separate occasions, with a minimum interval of twelve weeks between tests, to confirm persistent elevation, which is a key criterion for diagnosing APS. Each type of antibody (IgG and IgM) is reported separately, allowing for a comprehensive assessment of the patient's autoimmune status.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The test coded as CPT® 86146 is indicated for the evaluation of patients suspected of having antiphospholipid syndrome (APS). The following conditions may warrant the performance of this test:

  • Recurrent Venous Thrombosis Patients who experience multiple episodes of blood clots in the veins may be evaluated for APS to determine if an autoimmune process is contributing to their condition.
  • Recurrent Arterial Thrombosis Individuals with a history of repeated arterial clots may also be tested for the presence of beta 2 glycoprotein I antibodies to assess the risk of APS.
  • Fetal Losses Women who have experienced multiple unexplained fetal losses may be screened for APS, as the presence of these antibodies can be a contributing factor to pregnancy complications.

2. Procedure

The procedure for testing beta 2 glycoprotein I antibodies involves several key steps, which are outlined as follows:

  • Step 1: Blood Sample Collection A healthcare professional will collect a blood sample from the patient, typically via venipuncture. This sample is essential for the subsequent laboratory analysis to detect the presence of beta 2 glycoprotein I antibodies.
  • Step 2: Laboratory Analysis The collected blood sample is sent to a laboratory where it undergoes specific testing to measure the levels of anti-beta-2 glycoprotein I antibodies. Both IgG and IgM types of antibodies may be tested, and the results for each will be reported separately.
  • Step 3: Interpretation of Results After the laboratory analysis is complete, the results will be interpreted by a qualified healthcare provider. A persistently elevated level of either IgG or IgM antibodies, confirmed by testing on two separate occasions at least twelve weeks apart, is indicative of antiphospholipid syndrome.

3. Post-Procedure

Post-procedure care for patients undergoing testing for beta 2 glycoprotein I antibodies typically involves monitoring for any immediate complications related to blood sample collection, such as bruising or discomfort at the puncture site. Patients may be advised to follow up with their healthcare provider to discuss the results of the test. If the test indicates the presence of elevated antibodies, further evaluation and management strategies for antiphospholipid syndrome may be necessary, which could include additional testing or treatment options tailored to the patient's specific clinical situation.

Short Descr BETA-2 GLYCOPROTEIN ANTIBODY
Medium Descr BETA 2 GLYCOPROTEIN I ANTIBODY EACH
Long Descr Beta 2 Glycoprotein I antibody, each
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 3
CCS Clinical Classification 235 - Other Laboratory
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
GZ Item or service expected to be denied as not reasonable and necessary
Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
GA Waiver of liability statement issued as required by payer policy, individual case
Q4 Service for ordering/referring physician qualifies as a service exemption
77 Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
CR Catastrophe/disaster related
GW Service not related to the hospice patient's terminal condition
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
XE Separate encounter, a service that is distinct because it occurred during a separate encounter
Date
Action
Notes
2013-01-01 Changed Short Descriptor changed.
2001-01-01 Added First appearance in code book in 2001.
Code
Description
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"